Foamable Iodine Composition
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,575,739 | Foamable Iodine Composition In force · High confidence UsedRemaining | Vyne Therapeutics Inc. | In force | High confidence | ||
| US 8,119,106 | Foamable Iodine Compositions Lapsed Feb 21, 2024 on the fee record High confidence | Vyne Therapeutics Inc. | Lapsed Feb 21, 2024 on the fee record | High confidence | ||
| US 8,486,375 | Foamable Compositions Term ended · USPTO later recorded non-payment Aug 18, 2025 Term ended Apr 28, 2024 · Medium confidence | Vyne Therapeutics Inc. | Term ended USPTO later recorded non-payment Aug 18, 2025 | Term ended Apr 28, 2024 | Medium confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Vyne Therapeutics Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.